 |
|
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Wayne Huey-Herng Sheu (Sheu WHH), Siew Pheng Chan (Chan SP), Bien J. Matawaran (Matawaran BJ), Chaicharn Deerochanawong (Deerochanawong C), Ambrish Mithal (Mithal A), Juliana Chan (Chan J), Ketut Suastika (Suastika K), Chin Meng Khoo (Khoo CM), Huu Man Nguyen (Nguyen HM), Ji Linong (Linong J), Andrea Luk (Luk A), Kun-Ho Yoon (Yoon KH)
Diabetes Metab J. 2020;44(1):11-32. Published online 2020 Feb 21 DOI: https://doi.org/10.4093/dmj.2019.0208
|
|
Citations to this article as recorded by
 Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns
Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu, Jianhua Mao
Nephrology.2022; 27(2): 126. CrossRef Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
Angelo Cignarelli, Valentina Annamaria Genchi, Giulia Le Grazie, Irene Caruso, Nicola Marrano, Giuseppina Biondi, Rossella D’Oria, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino
Frontiers in Endocrinology.2022;[Epub] CrossRef Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi
Journal of Diabetes Investigation.2022;[Epub] CrossRef Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells
Li-Li Shi, Ming Hao, Zhou-Yun Jin, Gui-Fang Peng, Ying-Ying Tang, Hong-Yu Kuang, Yaoyao Bian
Disease Markers.2022; 2022: 1. CrossRef Relationship Between Four Non-Insulin-Based Indexes of Insulin Resistance and Serum Uric Acid in Patients with Type 2 Diabetes: A Cross-Sectional Study
Rongfeng Han, Yang Zhang, Xia Jiang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1461. CrossRef Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
Ernest A. Adeghate, Huba Kalász, Saeeda Al Jaberi, Jennifer Adeghate, Kornelia Tekes
Expert Opinion on Investigational Drugs.2021; 30(2): 85. CrossRef Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Jianping Weng, Longyi Zeng, Yuwei Zhang, Shen Qu, Xueying Wang, Ping Li, Liujun Fu, Boqing Ma, Shandong Ye, Jiao Sun, Weiping Lu, Zhiwen Liu, Daoxiong Chen, Zhifeng Cheng, Haiyan Liu, Tao Zhang, Jianjun Zou
Diabetes, Obesity and Metabolism.2021; 23(8): 1754. CrossRef How do you treat obesity in the elderly pharmacologically?
Claudio Daniel González, Guillermo Di Girolamo
Expert Opinion on Pharmacotherapy.2021; 22(13): 1639. CrossRef Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
Ayako Nagayama, Kenji Ashida, Miki Watanabe, Kanoko Moritaka, Aya Sonezaki, Yoichiro Kitajima, Hirokazu Takahashi, Satoko Yoshinobu, Shimpei Iwata, Junichi Yasuda, Nao Hasuzawa, Shuichi Ozono, Seiichi Motomura, Masatoshi Nomura
Frontiers in Endocrinology.2021;[Epub] CrossRef New Pandemic: Obesity and Associated Nephropathy
Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
Frontiers in Medicine.2021;[Epub] CrossRef Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro
Diabetes Research and Clinical Practice.2021; 180: 109067. CrossRef The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Mariana Tilinca, Robert Tiuca, Ioan Tilea, Andreea Varga
Journal of Personalized Medicine.2021; 11(12): 1249. CrossRef Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
Wayne H‐H Sheu
Journal of Diabetes Investigation.2020; 11(5): 1115. CrossRef SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients André J Scheen
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765. CrossRef SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho
Diseases.2020; 8(2): 14. CrossRef Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis ― An Update on Recent Findings ―
Kimie Tanaka, Daiju Fukuda, Masataka Sata
Circulation Journal.2020; 85(1): 2. CrossRef
|